| Literature DB >> 27980547 |
Przemysław Węglarz1, Michał Krejca2, Maria Trusz-Gluza2, Krystyna Bochenek2, Ewa Konarska-Kuszewska3, Krzysztof Szydło2, Piotr Kuszewski1, Christopher L Jackson4, Gianni D Angelini5, Grzegorz Bajor1.
Abstract
INTRODUCTION: The main limitation of coronary artery bypass grafting (CABG) is rapid neointimal hyperplasia leading to graft failure. AIM: To assess plaque formation in saphenous vein grafts (SVG) covered by an external Dacron stent in comparison with the classical technique.Entities:
Keywords: coronary artery bypass grafting; intravascular ultrasonography; neointima
Year: 2016 PMID: 27980547 PMCID: PMC5133322 DOI: 10.5114/aic.2016.63634
Source DB: PubMed Journal: Postepy Kardiol Interwencyjnej ISSN: 1734-9338 Impact factor: 1.426
Baseline characteristics of patients included in the study
| Parameter | Study group ( | Control group ( |
|
|---|---|---|---|
| Age [years] | 55.4 ±10.16 | 54.72 ±8.84 | 0.41 |
| Ejection fraction (%) | 54.64 ±6.21 | 54.23 ±6.2 | 0.72 |
| History of MI prior to CABG | 14 (35%) | 22 (34%) | 0.42 |
| History of PCI prior to CABG | 5 (12.5%) | 11 (16.9%) | 0.37 |
| Hypertension | 26 (65%) | 41 (63%) | 0.77 |
| Hypercholesterolaemia | 32 (80%) | 49 (75.4%) | 0.52 |
| Total cholesterol [mg/dl] | 209 ±38.3 | 207 ±46.62 | 0.47 |
| LDL cholesterol [mg/dl] | 130 ±40.22 | 127 ±76.36 | 0.46 |
| HDL cholesterol [mg/dl] | 43 ±8.08 | 44 ±11.62 | 0.43 |
| Triglyceride [mg/dl] | 155 ±78.04 | 145 ±72.58 | 0.16 |
| Creatinine [mg/dl] | 1.03 ±0.13 | 0.97 ±0.15 | 0.39 |
| Current smoker | 12 (30%) | 19 (29.3%) | 0.41 |
| History of smoking | 17 (42.5%) | 26 (40%) | 0.43 |
| Non-smoker | 11 (27.5%) | 20 (30.7%) | 0.42 |
Figure 1Stent ex-vivo and stented graft in-vivo (black arrow), regular graft (white arrow)
Figure 2Delineation of the neointima (red line) and the external elastic membrane (green line) in a saphenous vein bypass graft ultrasonogram
Angiography characteristics of saphenous vein grafts
| Vein grafts (analysed by angiography) | Control group | Study group |
|---|---|---|
| Number of saphenous vein grafts performed/patent (% of patent grafts): | 105/95 (90.5) | 47/37 (78.7) |
| 0 to 130 days | 36/34 (94.4) | 26/21 (80.8) |
| 130 to 260 days | 34/29 (85.3) | 11/8 (72.7) |
| 260 to 390 days | 35/32 (91.4) | 10/8 (80.0) |
Summary of IVUS analysis
| Time interval | Compartment volume | Control (mean ± SD) | External stent (mean ± SD) |
|---|---|---|---|
| 0 to 130 days | Lumen [mm3] | 10.90 ±3.9 | 10.33 ±4.4 |
| Plaque [mm3] | 1.59 ±2.21 | 0.86 ±1.24 | |
| Adventitia [mm3] | 8.61 ±2.26 | 7.98 ±1.89 | |
| SVG vessel [mm3] | 21.1 ±5.04 | 19.23 ±5.49 | |
| 130 to 260 days | Lumen [mm3] | 9.15 ±2.94 | 6.80 ±2.23* |
| Plaque [mm3] | 1.02 ±2.10 | 2.70 ±1.58* | |
| Adventitia [mm3] | 10.36 ±3.62 | 5.50 ±2.02* | |
| SVG vessel [mm3] | 20.54 ±6.16 | 15.13 ±4.14* | |
| 260 to 390 days | Lumen [mm3] | 8.92 ±2.93 | 5.69 ±1.26* |
| Plaque [mm3] | 1.36 ±1.73 | 3.29 ±2.66* | |
| Adventitia [mm3] | 9.47 ±2.67 | 6.46 ±2.55* | |
| SVG vessel [mm3] | 19.74 ±5.10 | 15.44 ±4.85* |
Figure 3Lumen volume and neointima (plaque) volume as determined by IVUS in control and stented saphenous vein grafts. Values are normalised to the measurement at the earliest time point. Bars show mean values with associated standard deviations; dark bars are control grafts, light bars are externally stented grafts (*p < 0.05)